Hassani Salah-Eddine, Chu William W, Wolfram Roswitha M, Kuchulakanti Pramod K, Xue Zhenyi, Gevorkian Natalie, Suddath William O, Satler Lowell F, Kent Kenneth M, Pichard Augusto D, Weissman Neil J, Waksman Ron
Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington, DC, USA.
J Invasive Cardiol. 2006 Jun;18(6):273-7.
We aimed to compare the clinical outcomes of dialysis versus nondialysis patients after coronary drug-eluting stent (DES) implantation.
The revascularization of ischemic heart disease in dialysis patients has remained controversial due to consistent exclusion of this population from major trials, especially in the context of percutaneous coronary interventions (PCI) with DES.
We analyzed the data on 3,442 consecutive patients who underwent PCI and DES implantation since March 2003. Periprocedural events, 1- and 6-month clinical outcomes were then compared between dialysis (n = 72) and nondialysis patients (n = 3,370).
Baseline characteristics revealed a higher prevalence of female gender (p = 0.03), African Americans (p < 0.001), hypertension (p < 0.001), diabetes mellitus (p < 0.001), number of diseased vessels (p = 0.04), lower ejection fraction (p < 0.001), and a higher prevalence of acute myocardial infarction (MI) (p = 0.04) in dialysis patients. Nondialysis patients showed more history of smoking (p < 0.001) and obesity (p = 0.02). Procedural success was higher (p = 0.05), while there was a trend toward a lower mortality rate, in the nondialysis group during hospitalization. At 6 months, the restenosis rate was low and comparable, but mortality occurred more often (16% vs. 3.8%; p < 0.001) in dialysis patients. Multivariate analysis revealed cardiogenic shock (p = 0.04) to be an independent predictor of mortality.
PCI with DES in dialysis patients is safe and feasible, with a similar reduction of repeat revascularization when compared with nondialysis patients. There was, however, a higher incidence of mortality in dialysis patients at 6 months, mostly influenced by contributing comorbidities and more severe conditions at presentation.
我们旨在比较冠状动脉药物洗脱支架(DES)植入术后透析患者与非透析患者的临床结局。
由于在主要试验中持续排除这一人群,尤其是在使用DES进行经皮冠状动脉介入治疗(PCI)的情况下,透析患者缺血性心脏病的血运重建一直存在争议。
我们分析了自2003年3月以来连续3442例接受PCI和DES植入的患者的数据。然后比较了透析患者(n = 72)和非透析患者(n = 3370)的围手术期事件、1个月和6个月的临床结局。
基线特征显示,透析患者中女性(p = 0.03)、非裔美国人(p < 0.001)、高血压(p < 0.001)、糖尿病(p < 0.001)、病变血管数量(p = 0.04)、射血分数较低(p < 0.001)以及急性心肌梗死(MI)患病率较高(p = 0.04)的情况更为普遍。非透析患者有更多吸烟史(p < 0.001)和肥胖史(p = 0.02)。住院期间,非透析组的手术成功率更高(p = 0.05),而死亡率有降低趋势。6个月时,再狭窄率较低且相当,但透析患者的死亡率更高(16%对3.8%;p < 0.001)。多变量分析显示心源性休克(p = 0.04)是死亡率的独立预测因素。
透析患者使用DES进行PCI是安全可行的,与非透析患者相比,重复血运重建的减少情况相似。然而,透析患者在6个月时的死亡率较高,主要受并存的合并症和就诊时更严重病情的影响。